Keywords: qlt, xenova, hit, termination, tariquidar, trials, nsclc

QLT and Xenova hit by termination of tariquidar trials in NSCLC

Article | 19 May 2003

Print This

QLT has discontinued its Phase III trials of tariquidar, licensed from the UK's Xenova, as an adjunctive treatment for patients ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in